住院患者急性肾损伤机器学习预测模型的开发
本研究为观察性队列研究,在2008年11月至2016年1月单中心三级城市学术医疗中心开展,纳入121158例入院时无预先存在肾衰竭的成人住院患者,使用人口学、生命体征、诊断和干预等电子健康记录数据通过梯度提升机算法预测基于血清肌酐的肾脏病改善全球结局2期急性肾损伤,60%数据用于推导、40%用于验证。验证队列中预测24小时内2期急性肾损伤的AUC为0.90(95%CI 0.90-0.90),48小时内为0.87(95%CI 0.87-0.87);预测48小时内接受肾脏替代治疗(n=821)的AUC为0.96(95%CI 0.96-0.96)。在概率阈值≥0.022时,模型对2期急性肾损伤的敏感性84%、特异性85%,并中位提前41小时(四分位距12-141小时)预测2期急性肾损伤的发生。结论认为常规电子健康记录数据可高精度预测即将发生的急性肾损伤,实时使用该模型可允许对高风险患者早期干预。
要点
- 在121158例成人住院患者中,17,482例(14.4%)发生任何KDIGO急性肾损伤,4,251例(3.5%)发生2期急性肾损伤。
- 验证队列预测24小时内2期急性肾损伤的AUC为0.90(95%CI 0.90-0.90),48小时内为0.87(95%CI 0.87-0.87)。
- 预测48小时内接受肾脏替代治疗(n=821)的AUC为0.96(95%CI 0.96-0.96)。
- 概率阈值≥0.022时,模型对2期急性肾损伤的敏感性84%、特异性85%,中位提前41小时(四分位距12-141小时)预测。
- 模型准确性在ICU、病房和急诊科等不同医院场景及入院血清肌酐分组间相似。
适用人群与场景
- 2008年11月至2016年1月单中心三级城市学术医疗中心的所有成人住院患者。
- 排除入院时存在预先肾衰竭者,定义为首次血清肌酐≥3.0 mg/dL、国际疾病分类第9版慢性肾脏病4期或更高编码,或首次血清肌酐测量后48小时内接受肾脏替代治疗。
诊断标准与关键阈值
- 预测目标为基于血清肌酐的肾脏病改善全球结局(KDIGO)2期急性肾损伤。
- 模型使用概率阈值≥0.022时,对2期急性肾损伤的敏感性84%、特异性85%。
研究设计与关键结果
- 观察性队列研究,单中心三级城市学术医疗中心,2008年11月至2016年1月,纳入121158例成人住院患者,60%数据用于推导、40%用于验证。
- 17,482例(14.4%)发生任何KDIGO急性肾损伤,4,251例(3.5%)发生2期急性肾损伤。
- 验证队列预测24小时内2期急性肾损伤的AUC为0.90(95%CI 0.90-0.90),48小时内为0.87(95%CI 0.87-0.87)。
- 预测48小时内接受肾脏替代治疗(n=821)的AUC为0.96(95%CI 0.96-0.96)。
- 概率阈值≥0.022时,模型对2期急性肾损伤的敏感性84%、特异性85%,中位提前41小时(四分位距12-141小时)预测2期急性肾损伤。
- 模型准确性在ICU、病房和急诊科等不同医院场景及入院血清肌酐分组间相似。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,实时使用该模型可允许对高风险急性肾损伤患者早期干预。
- 模型准确性在ICU、病房和急诊科等不同医院场景及入院血清肌酐分组间相似,提示可在这些场景中应用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop an acute kidney injury risk prediction model using electronic health record data for longitudinal use in hospitalized patients.
DESIGN: Observational cohort study.
SETTING: Tertiary, urban, academic medical center from November 2008 to January 2016.
PATIENTS: All adult inpatients without pre-existing renal failure at admission, defined as first serum creatinine greater than or equal to 3.0 mg/dL, International Classification of Diseases, 9th Edition, code for chronic kidney disease stage 4 or higher or having received renal replacement therapy within 48 hours of first serum creatinine measurement.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Demographics, vital signs, diagnostics, and interventions were used in a Gradient Boosting Machine algorithm to predict serum creatinine-based Kidney Disease Improving Global Outcomes stage 2 acute kidney injury, with 60% of the data used for derivation and 40% for validation. Area under the receiver operator characteristic curve (AUC) was calculated in the validation cohort, and subgroup analyses were conducted across admission serum creatinine, acute kidney injury severity, and hospital location. Among the 121,158 included patients, 17,482 (14.4%) developed any Kidney Disease Improving Global Outcomes acute kidney injury, with 4,251 (3.5%) developing stage 2. The AUC (95% CI) was 0.90 (0.90-0.90) for predicting stage 2 acute kidney injury within 24 hours and 0.87 (0.87-0.87) within 48 hours. The AUC was 0.96 (0.96-0.96) for receipt of renal replacement therapy (n = 821) in the next 48 hours. Accuracy was similar across hospital settings (ICU, wards, and emergency department) and admitting serum creatinine groupings. At a probability threshold of greater than or equal to 0.022, the algorithm had a sensitivity of 84% and a specificity of 85% for stage 2 acute kidney injury and predicted the development of stage 2 a median of 41 hours (interquartile range, 12-141 hr) prior to the development of stage 2 acute kidney injury.
CONCLUSIONS: Readily available electronic health record data can be used to predict impending acute kidney injury prior to changes in serum creatinine with excellent accuracy across different patient locations and admission serum creatinine. Real-time use of this model would allow early interventions for those at high risk of acute kidney injury.
参考来源
- Koyner JL, Carey KA, Edelson DP, et al. The Development of a Machine Learning Inpatient Acute Kidney Injury Prediction Model. Crit Care Med. 2018. PMID: 29596073. doi:10.1097/CCM.0000000000003123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。